NCT01955460View on ClinicalTrials.gov

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
BIOLOGICAL

Aldesleukin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

NGFR-transduced Autologous T Lymphocytes

Given IV

BIOLOGICAL

TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01955460 - Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | Biotech Hunter | Biotech Hunter